6833-47-2

Basic information

• Product Name: trans-4-Ethylcyclohexanecarboxylic acid
• Synonyms: TRANS-4-ETHYLCYCLOHEXANECARBOXYLIC ACID;4-trans-ethyl-cyclohexane carboxylic acid;4-ETHYL HEXAHYDROBENZOIC ACID;Trans-4-EthylcyclohexaneCarboxylicacid,2HaC9H16O2;trans-4-Ethylhexahydrobenzoic acid;2HA;4-trans-ethylcyclohexyl carboxylic acid;trans-4-Ethylcyclohe
• CAS NO: 6833-47-2
• Molecular Formula: C₉H₁₆O₂
• Molecular Weight: 156.22
• EINECS: 1312995-182-4
• Product Categories: Biphenyl & Diphenyl ether
• Mol File: 6833-47-2.mol

Chemical Properties

• Melting Point: 48-51°C
• Boiling Point: 252.5 °C at 760 mmHg
• Flash Point: 120 °C
• Appearance: /
• Density: 0.999 g/cm³
• Vapor Pressure: 0.00602mmHg at 25°C
• Refractive Index: 1.463
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 4.92±0.10(Predicted)
• CAS DataBase Reference: trans-4-Ethylcyclohexanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: trans-4-Ethylcyclohexanecarboxylic acid(6833-47-2)
• EPA Substance Registry System: trans-4-Ethylcyclohexanecarboxylic acid(6833-47-2)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-36-22
• Safety Statements: 26-36/37/39-37
• Hazardous Substances Data: 6833-47-2(Hazardous Substances Data)

Usage

Uses

Intermediates of Liquid Crystals

InChI:InChI=1/C9H16O2/c1-2-7-3-5-8(6-4-7)9(10)11/h7-8H,2-6H2,1H3,(H,10,11)/t7-,8-

Upstream product

• 619-64-7 p-ethylbenzoic acid 
• 622-96-8 4-methylethylbenzene 

Downstream Products

• 125533-06-4 (4-Ethyl-cyclohexyl)-acetic acid 
• 75839-86-0 trans-4-ethyl-cyclohexanemethanol 
• 81472-31-3 (trans-4-ethylcyclohexyl)methyl bromide 
• 93358-71-5 (4-Ethyl-cyclohexyl)-acetyl chloride 
• 125533-03-1 (4-Ethyl-cyclohexyl)-acetonitrile 
• 87002-26-4 [2-(4-Ethyl-cyclohexyl)-ethyl]-benzene 
• 92118-98-4 4-[2-(4-Ethyl-cyclohexyl)-ethyl]-benzoyl chloride 
• 125533-11-1 2-(4-Ethyl-cyclohexyl)-1-phenyl-ethanone 
• 72431-81-3 4-ethyl-1-methylcyclohexanecarboxylic acid 

Relevant articles and documents

Synthesis of Derivatives of 4-Ethylbenzoic and 4-Ethylcyclohexanecarboxylic Acids

A procedure has been developed for preparation of derivatives of 4-ethylbenzoic and 4-ethycyclohexanecarboxylic acids via liquid-phase catalytic oxidation and hydrogenation. From 4-ethylbenzoyl chloride the corresponding esters and N-arylamides have been synthesized, and from 4-ethylcyclohexanecarbonyl chloride, the corresponding N-arylamides.

THERAPEUTIC AGENT FOR DIABETES

A therapeutic agent for diabetes, which comprises a compound of the formula [I] wherein Xis a group of the formula wherein R4and R5are the same or different and each is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, and R6is a hydrogen atom or an amino-protecting group; R1is an optionally substituted alkyl having 1 to 5 carbon atoms, an optionally substituted alkenyl having 2 to 6 carbon atoms and the like, R2is a hydrogen atom, an optionally substituted alkyl having 1 to 5 carbon atoms and the like, R2' is a hydrogen atom, and R3is an optionally substituted alkyl having 1 to 5 carbon atoms and the like, a prodrug thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof. The compound of the present invention shows superior blood sugar decreasing action on the state of hyperglycemia, but does not affect the blood sugar when it is in the normal range or in the hypoglycemic state, which means that it is free of serious side effects such as hypoglycemia. Therefore, the compound of the present invention is useful as a therapeutic drug for diabetes and also useful as a preventive of the chronic complications of diabetes.

Design, synthesis and structure-activity relationship studies of novel 4,4-bis(trifluoromethyl)imidazolines as acyl-CoA: Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents

Novel 4,4-bis(trifluoromethyl)imidazolines have been found to be the potent acyl-CoA cholesterol acyltransferase (ACAT) inhibitors. ACAT is responsible for cholesterol esterification in the intestine, liver, and the arterial wall. These novel imidazolines

N-(Cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2

A series of analogues of N-(cyclohexylcarbonyl)-D-phenylalanine (5) have been synthesized and evaluated for their hypoglycemic activity. Relationships were studied between the activity and the three-dimensional structure of the acyl moiety, which was characterized by high-resolution 1H NMR spectroscopy and MNDO calculations. The role of the carboxyl group of the phenylalanine moiety was also studied by comparing the activities of the enantiomers, the decarboxyl derivative, the esters, and the amides of the phenylalanine derivatives. Thus, the structural requirements for possessing hypoglycemic activity was elucidated and a highly active compound, N-[(trans-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine (13) was obtained, which showed a 20% blood glucose decrease at an oral dose of 1.6 mg/kg in fasted normal mice.

The conformational free energy difference.for the trideuteromethyl substituent in cyclohexane

Studies at 169 K to 194 K of the 13C nmr spectrum of cis-1-ethyl--4-methylcyclohexane show that the conformational enthalpy difference -ΔH0 is 1.82 +/- 0.07 kcal mol-1 and the conformational entropy difference ΔS